BIIB
Biogen Inc
NASDAQ: BIIB · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$194.38
+6.00% today
Updated 2026-04-29
Market cap
$28.53B
P/E ratio
20.92
P/S ratio
2.88x
EPS (TTM)
$9.29
Dividend yield
—
52W range
$115 – $202
Volume
1.1M
Biogen Inc (BIIB) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
8 of 8
Last 8 quarters
Avg EPS surprise
+23.0%
Last 4 quarters
Revenue YoY growth
-7.1%
Most recent quarter
EPS YoY growth
-42.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+3.0%
Last 3 reports
Positive reaction rate
100%
3 of 3 quarters
Largest single-day move
+4.6%
2026-02-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-06 | $1.99 | +23.6% | $185.36 | $193.81 | +4.6% |
| 2025-10-29 | $4.81 | +24.9% | $149.13 | $149.61 | +0.3% |
| 2025-07-31 | $5.47 | +41.0% | $126.64 | $131.95 | +4.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $1.61 | $1.99 | +23.6% | $2.28B | -7.1% |
| 2025-09-30 | $3.85 | $4.81 | +24.9% | $2.45B | -0.4% |
| 2025-06-30 | $3.88 | $5.47 | +41.0% | $2.65B | +7.3% |
| 2025-03-31 | $2.95 | $3.02 | +2.4% | $2.43B | +6.1% |
| 2024-12-31 | $3.36 | $3.44 | +2.4% | $2.45B | +2.9% |
| 2024-09-30 | $3.79 | $4.08 | +7.7% | $2.47B | -2.5% |
| 2024-06-30 | $4.03 | $5.28 | +31.0% | $2.46B | +0.4% |
| 2024-03-31 | $3.45 | $3.67 | +6.4% | $2.29B | — |
| 2023-12-31 | $3.18 | $3.30 | +3.8% | $2.39B | — |
| 2023-09-30 | $3.97 | $4.36 | +9.8% | $2.53B | — |
| 2023-06-30 | $3.77 | $4.02 | +6.6% | $2.46B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $16.08 | $9.6B | +-2.7% | 28 | high |
| 2027 (E) | $17.50 | $10.2B | +5.9% | 28 | high |
| 2028 (E) | $19.25 | $11.1B | +8.8% | 28 | medium |
| 2029 (E) | $21.50 | $12.3B | +10.4% | 28 | medium |
| 2030 (E) | $24.00 | $13.8B | +12.7% | 28 | medium |
Frequently asked questions
Has Biogen Inc beaten earnings estimates?
Biogen Inc has beaten Wall Street EPS estimates in 8 of its last 8 quarterly reports, with an average EPS surprise of +23.0% over the last 4 quarters.
How does BIIB stock react to earnings?
BIIB stock has moved an average of +3.0% in the trading day following earnings over its last 3 reports, with positive reactions in 100% of those quarters.
What is Biogen Inc's revenue growth rate?
Biogen Inc reported year-over-year revenue growth of -7.1% in its most recent quarter, with EPS growing -42.2% year-over-year.
What is the expected EPS for BIIB in 2026?
Analysts expect Biogen Inc to report EPS of $16.08 for fiscal year 2026, on revenue of $9.6B, based on estimates from 28 analysts.